Asian Pacific Journal of Cancer Prevention

  • 제16권6호
  • /
  • Pages.2297-2301
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Feasibility of Photodynamic Diagnosis for Challenging TUR-Bt Cases Including Muscle Invasive Bladder Cancer, BCG Failure or 2nd-TUR

  • Takai, Tomoaki (Department of Urology, University Hospital, Osaka Medical College) ;
  • Inamoto, Teruo (Department of Urology, University Hospital, Osaka Medical College) ;
  • Komura, Kazumasa (Department of Urology, University Hospital, Osaka Medical College) ;
  • Yoshikawa, Yuki (Department of Urology, University Hospital, Osaka Medical College) ;
  • Uchimoto, Taizo (Department of Urology, University Hospital, Osaka Medical College) ;
  • Saito, Kenkichi (Department of Urology, University Hospital, Osaka Medical College) ;
  • Tanda, Naoki (Department of Urology, University Hospital, Osaka Medical College) ;
  • Kouno, Junko (Department of Urology, University Hospital, Osaka Medical College) ;
  • Minami, Koichiro (Department of Urology, University Hospital, Osaka Medical College) ;
  • Uehara, Hirofumi (Department of Urology, University Hospital, Osaka Medical College) ;
  • Takahara, Kiyoshi (Department of Urology, University Hospital, Osaka Medical College) ;
  • Hirano, Hajime (Department of Urology, University Hospital, Osaka Medical College) ;
  • Nomi, Hayahito (Department of Urology, University Hospital, Osaka Medical College) ;
  • Kiyama, Satoshi (Department of Urology, University Hospital, Osaka Medical College) ;
  • Azuma, Haruhito (Department of Urology, University Hospital, Osaka Medical College)
  • 발행 : 2015.04.03
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Despite widely adopted standard methods for follow-up including cystoscopy plus cytology, recurrence rates of non muscle-invasive bladder cancer (NMIBC) have not improved over the past decades, still ranging from 60% through 70%. Hence, widely acceptable surveillance strategies with excellent sensitivity are needed. Early recurrence has led to the development of a novel cystoscopy technique utilizing photodynamic diagnosis (PDD). Although, no studies have evaluated the efficacy of PDD for patients of MIBC, BCG failure or 2nd-transurethelial resection (TUR). Materials and Methods: The present study was performed from October 2012 through May 2013. IRB approved 25 patients initially underwent a cystoscopy examination of white light and blue light followed by the resection of tumors identified. Resections were performed from bladder mucosa areas considered suspicious at PDD, along with PDD negative normal bladder mucosa area resected by random biopsy. Specimens were divided into two groups, PDD positive and negative. Primary endpoints were sensitivity and specificity. Results: A total of 147 specimens extracted from 25 patients were included in the analysis. Some 45 out of 92 PDD-positive specimens were confirmed to have bladder cancer, and 51 out of PDD-negative 55 specimens were confirmed to be cancer negative. The sensitivity of PDD was 91.8% (45/49) and specificity was 52.0% (51/98). The sensitivity:specificity was 89.5% (17/19) : 47.6% (30/63) in 12 2nd-TUR patients, 90.5% (19/21) : 61.1% (11/18) in seven MIBC patients, and 95.0% (19/20) : 48.5% (16/33) in eight failed BCG cases. Conclusions: PDD-TURBT has high sensitivity to diagnose BC even for 2nd-TUR, MIBC or BCG failure cases.

키워드

참고문헌

  1. Babjuk M, Oosterlinck W, Sylvester R, et al (2011). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol, 59, 997-1008. https://doi.org/10.1016/j.eururo.2011.03.017
  2. Babjuk M, Soukup V, Petrik R, et al (2005). 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int, 96, 798-802. https://doi.org/10.1111/j.1464-410X.2004.05715.x
  3. Brausi M, Collette L, Kurth K, et al (2002). Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol, 41, 523-31. https://doi.org/10.1016/S0302-2838(02)00068-4
  4. Brausi M, Witjes JA, Lamm D, et al (2011). A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol, 186, 2158-67. https://doi.org/10.1016/j.juro.2011.07.076
  5. Daniltchenko DI, Riedl CR, Sachs MD, et al (2005). Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol, 174, 2129-33. https://doi.org/10.1097/01.ju.0000181814.73466.14
  6. Divrik RT, Sahin AF, Yildirim U, et al (2010). Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol, 58, 185-90. https://doi.org/10.1016/j.eururo.2010.03.007
  7. Filbeck T, Pichlmeier U, Knuechel R, et al (2002). Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol, 168, 67-71. https://doi.org/10.1016/S0022-5347(05)64833-1
  8. Fradet Y, Grossman HB, Gomella L, et al (2007). A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol, 178, 68-73. https://doi.org/10.1016/j.juro.2007.03.028
  9. Geavlete B, Multescu R, Georgescu D, et al (2012). Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)? BJU Int, 109, 549-56. https://doi.org/10.1111/j.1464-410X.2011.10374.x
  10. Grimbergen MC, van Swol CF, Jonges TG, et al (2003). Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol, 44, 51-6. https://doi.org/10.1016/S0302-2838(03)00210-0
  11. Grossman HB, Gomella L, Fradet Y, et al (2007). A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol, 178, 62-7. https://doi.org/10.1016/j.juro.2007.03.034
  12. Hermann GG, Mogensen K, Carlsson S, et al (2011). Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int, 108, 297-303. https://doi.org/10.1111/j.1464-410X.2011.10090.x
  13. Jichlinski P, Guillou L, Karlsen SJ, et al (2003). Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. J Urol, 170, 226-9. https://doi.org/10.1097/01.ju.0000060782.52358.04
  14. Jocham D, Stepp H, Waidelich R (2008). Photodynamic diagnosis in urology: state-of-the-art. Eur Urol, 53, 1138-48. https://doi.org/10.1016/j.eururo.2007.11.048
  15. Jocham D, Witjes F, Wagner S, et al (2005). Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol, 174, 862-6. https://doi.org/10.1097/01.ju.0000169257.19841.2a
  16. Leibovici D, Kassouf W, Pisters LL, et al (2007). Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology, 70, 473-6. https://doi.org/10.1016/j.urology.2007.05.007
  17. Morales A (1984). Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer. J Urol, 132, 457-9.
  18. Mostafid H, Brausi M (2012). Measuring and improving the quality of transurethral resection for bladder tumour (TURBT). BJU Int, 109, 1579-82. https://doi.org/10.1111/j.1464-410X.2011.10638.x
  19. Riedl CR, Daniltchenko D, Koenig F, et al (2001). Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol, 165, 1121-3. https://doi.org/10.1016/S0022-5347(05)66442-7
  20. Schmidbauer J, Witjes F, Schmeller N, et al (2004). Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol, 171, 135-8. https://doi.org/10.1097/01.ju.0000100480.70769.0e
  21. Stenzl A, Burger M, Fradet Y, et al (2010). Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol, 184, 1907-13. https://doi.org/10.1016/j.juro.2010.06.148
  22. Stenzl A, Jocham D, Jichlinski P, et al (2008). Photodynamic diagnostics in the urinary tract. consensus paper of the working group for oncology of the german society for urology. Urologe A, 47, 982-7. https://doi.org/10.1007/s00120-008-1791-5
  23. Sylvester RJ, van der MA, Lamm DL (2002). Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol, 168, 1964-70. https://doi.org/10.1016/S0022-5347(05)64273-5
  24. Zaak D, Hofstetter A (2002). The current diagnosis of superficial bladder cancer must be reconsidered. Urol Int, 69, 85-90. https://doi.org/10.1159/000065552
  25. Zaak D, Kriegmair M, Stepp H, et al (2001). Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology, 57, 690-4. https://doi.org/10.1016/S0090-4295(00)01053-0

피인용 문헌

  1. Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection vol.37, pp.5, 2017, https://doi.org/10.3892/or.2017.5570
  2. Can bladder preservation therapy come to the center stage? pp.09198172, 2017, https://doi.org/10.1111/iju.13495